Caliway Biopharmaceuticals Co., Ltd. (6919) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Caliway Biopharmaceuticals Co., Ltd. (6919:TWSE), powered by AI.

Current Price
$611.00
P/E Ratio
-155.0
Market Cap
75.7B
Sector
Healthcare
What is the Caliway Biopharmaceuticals Co., Ltd. stock price forecast?

Caliway Biopharmaceuticals Co., Ltd. is currently trading at $611.00. View real-time AI analysis on Alpha Lenz.

What is Caliway Biopharmaceuticals Co., Ltd. insider trading activity?

View the latest insider trading data for Caliway Biopharmaceuticals Co., Ltd. on Alpha Lenz.

What is Caliway Biopharmaceuticals Co., Ltd.'s P/E ratio?

Caliway Biopharmaceuticals Co., Ltd.'s P/E ratio is -155.0.

Caliway Biopharmaceuticals Co., Ltd.

TWSE · 6919
NT$611.00+0.00(+0.00%)
Ask about Caliway Biopharmaceuticals Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Caliway Biopharmaceuticals Co., Ltd. trades at a P/E of -155.0 (undervalued) with modest ROE of -19.9%.

Ask for details

Company Overview

Caliway Biopharmaceuticals Co., Ltd. is a company specializing in the development and commercialization of innovative pharmaceutical products. Its primary function is to advance medical treatments through its robust pipeline of therapies, focusing on unmet medical needs in areas such as dermatology, neurology, and oncology. The biopharmaceutical firm aims to transform cutting-edge research into accessible healthcare solutions, with a particular emphasis on injectable treatments and small molecule drugs. Caliway Biopharmaceuticals operates within the highly dynamic and competitive biotechnology and pharmaceuticals sector, which is crucial for advancing medical science and improving patient outcomes. Its significant role in the market lies in its focus on innovation and addressing niche therapeutic areas, which can generate substantial benefits for the healthcare community as well as providing solutions that potentially improve quality of life. Headquartered in a strategic location with access to research facilities and partnerships, Caliway Biopharmaceuticals embodies a commitment to pushing the boundaries of modern medicine.

CEOMs. Yufang Ling
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2023

Profile

NT$75.69BMarket Cap
NT$38.93MRevenue
0.00Shares Out
0Employees

Margins

70.56%Gross
-1181.78%EBITDA
-1318.88%Operating
-1254.64%Pre-Tax
-1254.64%Net

Valuation

-154.97P/E
20.23P/B
1944.26EV/Sales
-157.13EV/EBITDA
-174.56P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-19.31%ROA
-19.92%ROE
-19.29%ROIC

Financial Health

NT$3.42BCash & Cash Equivalents
NT$-3.34BNet Debt
2.29%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Caliway Biopharmaceuticals Co., Ltd. (ticker: 6919) is a company listed on TWSE in the Healthcare sector (Biotechnology). Market cap is $75.7B.

The current price is 611 with a P/E ratio of -154.97x and P/B of 20.23x.

ROE is -19.92% and operating margin is -1318.88%. Annual revenue is $39M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Caliway Biopharmaceuticals Co., Ltd. (6919) Stock Forecast 2026 $611.00 — Price, Financials & Analyst Targets | Alpha Lenz